Skyrizi launch beats expectations again as AbbVie looks to post-Humira future

Recently launched psoriasis drug Skyrizi exceeded sales expectations for the second quarter in a row, as immunology and hemato-oncology drugs continue to drive AbbVie’s growth ahead of anticipated U.S. biosimilar competition for Humira.

Sales of Skyrizi risankizumab in 3Q19 were $91 million, beating the Street’s $86 million consensus. From its launch in May through Sept. 30, sales of the drug have amounted to $139 million, prompting AbbVie Inc. (NYSE:ABBV) to again lift Skyrizi’s full-year sales guidance to $275 million from $250 million...